Metastatic prostate cancer (PCa) inevitably acquires resistance to standard therapy
preceding lethality. Here, we unveil a chromosomal instability (CIN) tolerance mechanism as …

Pancreatic adenocarcinoma (PDAC) is disease with a 5-year survival of only 12%. Many
patients with PDAC present with late-stage disease and even early-stage disease can often …

Colorectal cancer (CRC) is a leading cause of the cancer-related deaths worldwide. Thus,
developing novel and targeted therapies for inhibiting CRC progression and metastasis is …

Microtubule-associated serine/threonine kinase-like (MASTL) regulates mitotic progression
and is an attractive target for the development of new anticancer drugs. In this study, novel …

Phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP) has been
reported to be a new tumor suppressor with a significant inhibitory effect in various cancers …

Background The repurposing of FDA-approved drugs for anti-cancer therapies is appealing
due to their established safety profiles and pharmacokinetic properties and can be quickly …

Kinase is an enzyme that helps in the phosphorylation of the targeted molecules and can
affect their ability to react with other molecules. So, kinase influences metabolic reactions …

Background: A diagnosis of pancreatic cancer is pretty grim. Saikosaponin-A (SSA) is a
Chinese herbal extract with anticancer activity. However, the therapeutic effect of SSA on …

Platinum-based chemotherapy is the standard first-line treatment for oral squamous cell
carcinoma (OSCC) that is inoperable, recurrent, or metastatic. Platinum sensitivity is a major …

Background Metastasis of advanced lung adenocarcinoma (LUAD) is a key cause of cancer-
related death, and angiogenesis is the main feature of tumor growth and metastasis …